1600 Clifton Road, N.E., Mailstop H24-8
Atlanta, GA 30329-4027
To receive email updates about this page, enter your email address:
ACIP approved the following recommendations by majority vote at its June 22-23, 2022 meeting:
- ACIP recommends that adults aged ≥65 years preferentially receive one of the following influenza vaccines: quadrivalent high-dose inactivated influenza vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (aIIV4). If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be used.
- Affirm the updated MMWR Recommendations and Reports, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022-23 Influenza Season.”
- PCV15 (15-valent pneumococcal conjugate vaccine) may be used as an option to PCV13 (13-valent pneumococcal conjugate vaccine) for children aged <19 years according to currently recommended PCV13 dosing and schedules.
- MMR vaccine (Priorix, GSK) according to currently recommended schedules and off-label uses as an option to prevent measles, mumps, and rubella.
These recommendations have been adopted by the CDC Director and will become official once published in MMWR.